ClinicalTrials.gg
CompletedNCT03294304Updated Dec 16, 2021Results posted

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

A Phase 2 interventional study of Nivolumab and Cisplatin in Muscle Invasive Bladder Cancer, sponsored by Masonic Cancer Center, University of Minnesota. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-16.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 10 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.

Enrollment
19th of 25
43 · median 76
Started
2018
with 5 others
Phase 2
13 of 25
1 open now
Registered
6th of 25
by date

Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 19th largest by enrollment, is one of 6 that started in 2018, is one of 13 in phase 2, and was the 6th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing nivolumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with muscle-invasive bladder cancer (MIBC) prior to standard of care radical cystectomy. Patients will receive neoadjuvant treatment with nivolumab in combination with gemcitabine-cisplatin (GC) every 3 weeks for 4 treatment cycles over 12 weeks followed by standard of care radical cystectomy.

03

Conditions studied

  • Muscle Invasive Bladder Cancer

Keywords

  • MIBC
  • UC
  • Immunotherapy
  • Bladder Cancer
  • Neoadjuvant
  • Nivolumab
  • Cisplatin
  • Gemcitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MIBC (predominantly urothelial carcinoma) with clinical stage T2-T4a and N\<1 disease (solitary lymph node measuring \< 2 cm) and M0 and deemed eligible for radical cystectomy.
  • Age ≥ 18 years
  • Performance Status of 0 or 1.
  • Required initial laboratory values within 14 days of study enrollment:

    • ≥ 1500 cells/mm\^3
    • ≥ 100,000 cells/mm\^3
    • ≥ 9.0 g/dL
    • ≤ 1.5 times the (ULN) for the institution (For patients with known Gilbert's disease: bilirubin ≤ 3 x ULN)
    • (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN for the institution
    • ≥ 50 ml/min by Cockcroft-Gault formula or 24 hour urinary clearance (CrCl = [140-age (years)] x actual weight (kg) / [72 x serum Cr (mg/dL)] (if patient is female multiply the above by 0.85) or 24 hour urinary creatinine clearance.
    • Alkaline phosphatase ≤ 2.5 x ULN for the institution
    • and aPTT ≤ 1.5 x ULN if not on therapeutic anticoagulation. Patients receiving therapeutic anticoagulation will be allowed if maintained on a stable dose.
  • Females of and males who are not surgically sterile and with partners of childbearing potential must agree to use effective during study treatment for 5 months for females and 7 months for males after the last dose of nivolumab.
  • Ability to provide a signed and dated consent or have a legally authorized representative to provide written and signed consent prior to the initiation of any research related procedures.
  • Patient must agree to submission of archived tumor (20-25 formalin-fixed paraffin embedded (FFPE) slides of 5-10 microns in thickness) from TURBT and radical cystectomy tissues. If archived samples are not available fresh tissue will be used.
  • Ability to provide written consent prior to the initiation of any research related procedures.

Exclusion criteria

Exclusion Criteria:

  • Presence of N2-3 or M1 disease.
  • Ineligible to receive cisplatin by meeting one or more of the following criteria;

    • of \< 50 mL/min
    • Hearing loss of 25 dB at two contiguous frequencies with testing required if a patient has hearing loss - At the investigator's discretion, and after discussion with the patient, this exclusion may be waived if the potential benefit of cisplatin therapy is felt to outweigh the risk of further hearing loss.
    • v4 Grade 2 or higher peripheral neuropathy,
    • Class III or IV heart failure
    • performance status 2 or higher.
  • Prior systemic therapy (intravenous) is not permitted. Prior intravesical therapies including intravesical gemcitabine is permitted for non-muscle invasive disease (i.e. T1 or lower).
  • Prior treatment with cisplatin for bladder cancer.
  • Prior treatment with , CTLA-4, or anti-PD-L1 therapeutic antibody or pathway-targeting agents.
  • Prior therapeutic radiation to the bladder.
  • Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study.
  • Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure (>New York Heart Association Class 2), stroke, serious cardiac arrhythmia.
  • (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness.
  • Pregnancy, lactation, or breast-feeding. Women of must have a negative urine pregnancy test at screening.
  • History of disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Wegener's granulomatosis, vascular thrombosis associated with antiphospholipid syndrome, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, systemic vasculitis, or glomerulonephritis.
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan, history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Active virus (HBV, chronic or acute, defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or antibody. Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to Cycle 1, Day 1 and confirmed to be negative. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • Active tuberculosis or BCG infection
  • Active infection requiring systemic antibiotics for more than 7 days within 3 days prior to Cycle 1, Day 1. Prophylactic short-term antibiotics will be allowed.
  • Administration of intravesical bacillus Calmette-Guerin (BCG) within 4 weeks before Cycle 1, Day 1
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a will be required during the study.
  • Persisting toxicity from prior therapy (NCI CTCAE v4.03 Grade >1); however alopecia or other Grade \<2 AEs not constituting a safety risk, based on Investigator's judgement, are acceptable.
  • History of or active bone marrow disorders expected to interfere with study therapy (e.g. acute leukemias, accelerated/blast-phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma).
  • Prior allogeneic stem cell or solid organ transplant.
  • Known primary central nervous system (CNS) .
  • Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted but patients with psoriasis require a baseline ophthalmologic exam to rule out ocular manifestations. Rash must cover less than 10% of body surface area (BSA) and must be well controlled at baseline and only requiring topical .
  • Any other chronic medical condition or psychiatric condition, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
  • Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy. Patients on androgen deprivation therapy as part of therapy after radiation for prostate cancer or patients on adjuvant hormonal therapies for breast cancer will be allowed if they are being considered for curative intent for bladder cancer.
  • Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-a or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to Cycle 1, Day 1
  • Concomitant use of systemic corticosteroids at physiologic doses or \<10 mg/day of prednisone or equivalent.
  • Concomitant use of another investigational agent and/or treatment with an investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within five halflives of the investigational product, whichever is longer).
  • Use of bisphosphonate therapy for osteoporosis will be allowed if started prior to study enrollment.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Nivolumab, Cisplatin, & Gemcitabine

    Drug: Nivolumab · Drug: Cisplatin · Drug: Gemcitabine

Interventions

  • Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.

    Also known as: Opdivo

  • Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.

    Also known as: Platinol

  • Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)

    Incidence of Measurable Disease "pT" in the TNM staging system refers to the size and extend of the primary tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b. pTa refers to noninvasive papillary carcinoma. pTis refers to carcinoma in situ (CIS) or a "flat tumor" stage. pN refers to lymph nodes. N0 mans cancer has not spread to nearby lymph nodes.

    Time frame: Surgery Day 1

Secondary outcomes

  1. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treatment Day 1 of cycle 1

  2. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treatment Day 8 of cycle 1

  3. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treatment Day 1 of cycle 2

  4. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treament day 8 of cycle 2

  5. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treatment day 1 of cycle 3

  6. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treatment day 8 of cycle 3

  7. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treatment day 1 of cycle 4

  8. Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)

    Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

    Time frame: Treatment day 8 of cycle 4

  9. Safety of Nivolumab With Gemcitabine/Cisplatin

    Incidence of Adverse Events

    Time frame: 30 Days +/- 7 Days after last chemotherapy

  10. Safety of Nivolumab With Gemcitabine/Cisplatin

    Incidence of Adverse Events

    Time frame: 4 weeks post radical cystectomy

  11. Count of Participants Experiencing Progression Free Survival (PFS)

    Count of participants experiencing Progression Free Survival (PFS)

    Time frame: Every 3 Months for 2 Years

07

Results

Posted Dec 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneNivolumab, Cisplatin, & Gemcitabine
Started43
Completed43
Not completed0

Outcome measures

PrimaryPathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)

Incidence of Measurable Disease "pT" in the TNM staging system refers to the size and extend of the primary tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b. pTa refers to noninvasive papillary carcinoma. pTis refers to carcinoma in situ (CIS) or a "flat tumor" stage. pN refers to lymph nodes. N0 mans cancer has not spread to nearby lymph nodes.

Time frame:
Surgery Day 1
Reported as:
Count of participants · Participants
Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)27
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treatment Day 1 of cycle 1
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)7
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treatment Day 8 of cycle 1
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 1)27
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treatment Day 1 of cycle 2
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)18
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treament day 8 of cycle 2
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 2)15
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treatment day 1 of cycle 3
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)16
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treatment day 8 of cycle 3
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 3)13
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treatment day 1 of cycle 4
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)8
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)

Count of participants with Adverse Events related to Nivolumab with Gemcitabine/Cisplatin

Time frame:
Treatment day 8 of cycle 4
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin (Cycle 4)11
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin

Incidence of Adverse Events

Time frame:
30 Days +/- 7 Days after last chemotherapy
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin5
SecondarySafety of Nivolumab With Gemcitabine/Cisplatin

Incidence of Adverse Events

Time frame:
4 weeks post radical cystectomy
Reported as:
Count of participants · Participants
Safety of Nivolumab With Gemcitabine/Cisplatin
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Safety of Nivolumab With Gemcitabine/Cisplatin24
SecondaryCount of Participants Experiencing Progression Free Survival (PFS)

Count of participants experiencing Progression Free Survival (PFS)

Time frame:
Every 3 Months for 2 Years
Reported as:
Count of participants · Participants
Count of Participants Experiencing Progression Free Survival (PFS)
ParticipantsNivolumab, Cisplatin, & Gemcitabine
Count of Participants Experiencing Progression Free Survival (PFS)36

Adverse events

Collected over 120 days after last dose nivolumab. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab, Cisplatin, & Gemcitabine7/43 (16.3%)11/43 (25.6%)42/43 (97.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventNivolumab, Cisplatin, & Gemcitabine
General disorders and administration site conditions - Other, specifyGeneral disorders2/43
Thromboembolic eventVascular disorders2/43
AnemiaBlood and lymphatic system disorders1/43
DehydrationMetabolism and nutrition disorders1/43
FatigueGeneral disorders1/43
Febrile neutropeniaBlood and lymphatic system disorders1/43
FeverGeneral disorders1/43
HyponatremiaMetabolism and nutrition disorders1/43
Nervous system disorders - Other, specifyNervous system disorders1/43
Neutrophil count decreasedInvestigations1/43
Most frequent other events
Showing 10 of 133
Most frequent other events
EventNivolumab, Cisplatin, & Gemcitabine
NauseaGastrointestinal disorders31/43
FatigueGeneral disorders30/43
AnemiaBlood and lymphatic system disorders25/43
ConstipationGastrointestinal disorders24/43
Neutrophil count decreasedInvestigations20/43
White blood cell decreasedInvestigations18/43
HypertensionVascular disorders15/43
General disorders and administration site conditions - Other, specifyGeneral disorders13/43
Platelet count decreasedInvestigations13/43
Rash maculo-papularSkin and subcutaneous tissue disorders13/43

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nivolumab, Cisplatin, & Gemcitabine
<=18 years0
Between 18 and 65 years21
>=65 years22
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Nivolumab, Cisplatin, & Gemcitabine
Male15
Female26
Unknown2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab, Cisplatin, & Gemcitabine
Hispanic or Latino1
Not Hispanic or Latino34
Unknown or Not Reported8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab, Cisplatin, & Gemcitabine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White31
More than one race0
Unknown or Not Reported12
Region of Enrollment
Region of Enrollment(participants)Nivolumab, Cisplatin, & Gemcitabine
United States43
08

Study locations

3 sites
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Masonic Cancer Center - University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Huntsman Cancer Institute - University of Utah Health
    Salt Lake City, Utah 84112, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jun 2020, 28 months.

Results were first posted in Dec 2021, 1 year 6 months after primary completion.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's 28 months is below that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2017
First posted
Sep 27, 2017
StartActual
Jan 29, 2018
Primary completionActual
Jun 5, 2020
CompletionActual
Jul 1, 2021
Results first posted
Dec 16, 2021
Last update
Dec 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03294304
Responsible party
Sponsor
First posted
Sep 27, 2017
Start date
Jan 29, 2018
Primary completion
Jun 5, 2020
Completion
Jul 1, 2021
Results posted
Dec 16, 2021
Last update
Dec 16, 2021

Study contacts

Badrinath Konety, MD, MBA
principal investigator · Masonic Cancer Center, University of Minnesota
Shilpa Gupta, MD
study chair · Cleveland Clinic Taussig Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Cisplatin · Gemcitabine

Start the discussion